-
Nuvation Bio NEW YORK STOCK EXCHANGE INC.:NUVB Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco.
Location: | Website: www.nuvationbio.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
454.9M
Cash
549.1M
Avg Qtr Burn
-24.79M
Short % of Float
4.84%
Insider Ownership
26.86%
Institutional Own.
44.60%
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Taletrectinib (ROS1 inhibitor) Details Cancer, Non-small cell lung carcinoma | NDA Submission | |
Safusidenib [mIDH1 inhibitor] Details Cancer, High-grade Glioma
| Phase 2 Data readout | |
NUV-1511 Details Solid tumor/s | Phase 1/2 Data readout | |
NUV-868 +enzalutamide Details Cancer, Solid tumor/s, Castration-resistant prostate cancer | Phase 1b Data readout | |
NUV-868 +olaparib Details Solid tumor/s, Cancer, Pancreatic cancer, Ovarian cancer, Castration-resistant prostate cancer, Triple-negative breast cancer | Phase 1b Data readout | |
NUV-868 (BD2-Selective BETi) Details Cancer, Solid tumor/s | Phase 1 Data readout | |
NUV-422 (CDK inhibitor) Details High-grade Glioma
, Solid tumor/s, Cancer, Prostate cancer, Breast cancer, Castration-resistant prostate cancer, Metastatic breast cancer | Failed Discontinued |